MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Genocea Biosciences Company Profile (NASDAQ:GNCA)

Consensus Ratings for Genocea Biosciences (NASDAQ:GNCA) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.80 (438.86% upside)

Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Needham & Company LLCReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Stifel NicolausBoost Price TargetBuy$11.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/19/2015Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2015Cowen and CompanyReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Genocea Biosciences (NASDAQ:GNCA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.42)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415($0.40)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.43)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.51)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.57)($0.64)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414($0.55)($0.66)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.51)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q2($0.42)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114($0.52)($0.76)$0.26 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.39)($0.39)($0.39)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.44)($0.44)($0.44)
Q4 20161($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)
Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Genocea Biosciences (NASDAQ:GNCA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/9/2016Jonathan PooleCFOBuy4,000$3.88$15,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015William D ClarkCEOBuy3,800$6.45$24,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Jessica Baker FlechtnerVPSell2,229$11.35$25,299.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Polaris Venture Management Co.Major ShareholderSell30,004$13.04$391,252.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Polaris Venture Management Co.Major ShareholderSell10,618$13.01$138,140.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Polaris Venture Management Co.Major ShareholderSell46,000$13.24$609,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Jessica Baker FlechtnerVPSell2,229$10.52$23,449.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Jessica Baker FlechtnerVPSell2,229$10.21$22,758.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Jessica Baker FlechtnerVPSell2,283$11.77$26,870.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Stephen J HoffmanDirectorBuy700,000$8.25$5,775,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Jessica Baker FlechtnerVPSell4,699$8.50$39,941.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Jessica Baker FlechtnerVPSell6,435$12.00$77,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Paul GiannascaVPSell4,071$11.84$48,200.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Paul GiannascaVPSell834$12.35$10,299.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Paul GiannascaVPSell2,455$12.43$30,515.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Paul GiannascaVPSell2,970$12.80$38,016.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Paul GiannascaVPSell6,760$12.50$84,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Polaris Venture Management Co.Major ShareholderSell9,660$13.01$125,676.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Polaris Venture Management Co.Major ShareholderSell63,794$13.28$847,184.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Plc GlaxosmithklineInsiderBuy143,773$12.00$1,725,276.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Polaris Venture Management Co.Major ShareholderBuy232,820$12.00$2,793,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Stephen J HoffmanDirectorBuy250,931$12.00$3,011,172.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
DateHeadline
06/27/16 04:09 PMBroker Outlook For The Week Ahead Genocea Biosciences Inc (GNCA) - Fiscal Standard
06/27/16 08:41 AMStrong Sell Calls Recommendations For Genocea Biosciences, Inc. (NASDAQ:GNCA) At 0 - Investor Newswire
06/27/16 08:41 AMGenocea Biosciences Incorporated (NASDAQ:GNCA) Sellers Covered 4.84% of Their Shorts - Engelwood Daily
06/25/16 08:06 AMHC Stocks Broker Alerts: Baxter International Inc (NYSE:BAX), Genocea Biosciences Inc (NASDAQ:GNCA) - share market updates (press release)
06/25/16 08:06 AMGenocea Biosciences Inc. (GNCA) Jumps 26.56% on June 23 - Equities.com
06/20/16 04:04 PMThis Weeks Broker Views For Genocea Biosciences Inc (GNCA) - Fiscal Standard
06/19/16 08:33 AMStrong Buy Calls Count For Genocea Biosciences, Inc. (NASDAQ:GNCA) At 4 - Investor Newswire
06/17/16 04:08 AMGenocea Biosciences Inc (GNCA) Current Analyst Ratings - Fiscal Standard
06/16/16 08:35 AMGenocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
06/14/16 03:49 PMcooper ronald harold wilfred - [at noodls] - FORM 3 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 1.... This is an abstract of the original noodl. To continue reading this document, click here for the original ...
06/11/16 04:20 AMGenocea Biosciences Inc. (GNCA) Drops 5.38% on June 09 - Equities.com
06/10/16 03:49 PMcooper, ronald harold wilfred - [at noodls] - FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ... This is an abstract of the original noodl. To continue reading this document, ...
06/09/16 04:49 PMcurrent report - [at noodls] - Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. ... This is an abstract of the original noodl. ...
06/09/16 04:24 PMGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/09/16 03:49 PMGenocea Appoints Ron Cooper to Board of Directors - [at noodls] - CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Ron ...
06/08/16 04:32 PMGENOCEA BIOSCIENCES INC. (NASDAQ:GNCA) Financial Condition Compared to S&P 500 - CML News
06/07/16 03:22 PMGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/04/16 04:16 PMGenocea Biosciences Inc. (GNCA) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/02/16 04:29 AMGenocea Biosciences Inc (GNCA) is Trading Higher on Unusual Volume for May 31 - Equities.com - Genocea Biosciences Inc (GNCA) is Trading Higher on Unusual Volume for May 31Equities.comGenocea Biosciences Inc (GNCA) experienced unusually high volume on May. 31, as the stock gained 18.09% to a closing price of $4.70. The stock saw 1.55 million shares trade hands over the course of the day on 5,380 trades. Given that the stock's ...Buy, Sell Or Hold Rating For Genocea Biosciences Inc (GNCA)?Share Trading NewsInsiders Are Gradually Buying Genocea Biosciences, Inc. (NASDAQ:GNCA)HNNall 3 news articles »
06/01/16 10:35 PMInsiders Are Gradually Buying Genocea Biosciences, Inc. (NASDAQ:GNCA) - HNN - Insiders Are Gradually Buying Genocea Biosciences, Inc. (NASDAQ:GNCA)HNNAccording to the latest SEC filings, insiders at Genocea Biosciences, Inc. (NASDAQ:GNCA) have increased their position in the stock by 10.44% over the past 6 months. Insiders now own 0.30% of total outstanding shares. There are both legal and illegal ...
06/01/16 04:32 PMInvestor's observing Biotech Stocks: MannKind Corporation (NASDAQ:MNKD) , Genocea Biosciences, Inc. (NASDAQ ... - Is stories - Is storiesInvestor's observing Biotech Stocks: MannKind Corporation (NASDAQ:MNKD) , Genocea Biosciences, Inc. (NASDAQ ...Is storiesIn most recently trading session on 5/31/2016, Genocea Biosciences, Inc. (NASDAQ:GNCA) climbed +18.09% while traded on 1.55 million shares versus it's an average volume of 1.32 million shares. The company recorded the last trade with the price of ...and more »
05/31/16 04:26 PMGenocea Biosciences Inc (GNCA) Jumps 18.09% on May 31 - Equities.com - Genocea Biosciences Inc (GNCA) Jumps 18.09% on May 31Equities.comGenocea Biosciences Inc (GNCA) was among the biggest gainers on the Russell 2000 for Tuesday May 31 as the stock popped 18.09% to $4.70, representing a gain of $0.72 per share. Some 1.55 million shares traded hands on 5,380 trades, compared with ...New Relic, Inc. (NYSE:NEWR) rose 5.70%: Genocea Biosciences, Inc. (NASDAQ:GNCA), Genomic Health Inc ...Benchmark Monitorall 3 news articles »
05/29/16 07:59 AMHow Many Genocea Biosciences Inc (NASDAQ:GNCA)'s Analysts Are Bullish? - HNN - How Many Genocea Biosciences Inc (NASDAQ:GNCA)'s Analysts Are Bullish?HNNOut of 6 analysts covering Genocea Biosciences (NASDAQ:GNCA), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genocea Biosciences has been the topic of 5 analyst reports since August 6, 2015 according to StockzIntelligence Inc.and more »
05/26/16 05:09 PMBig Movers: Genocea Biosciences, Inc. (NASDAQ:GNCA), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), PharmAthene ... - KC Register - Big Movers: Genocea Biosciences, Inc. (NASDAQ:GNCA), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), PharmAthene ...KC RegisterOn 23 May, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced that John E. Bishop, Ph.D. has joined the company as senior vice president of pharmaceutical sciences. On Wednesday Genocea Biosciences, Inc. (NASDAQ:GNCA) share price closed at ...
05/26/16 08:21 AMInsiders Are Gradually Buying Genocea Biosciences, Inc. (NASDAQ:GNCA) - Wall Street Hints and News - Insiders Are Gradually Buying Genocea Biosciences, Inc. (NASDAQ:GNCA)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Genocea Biosciences, Inc. (NASDAQ:GNCA) have increased their position in the stock by 11.40% over the past 6 months. Insiders now own 0.30% of total outstanding shares. There are both legal and illegal ...and more »
05/24/16 10:18 PMBroker Roundup For Genocea Biosciences Inc (GNCA) - Share Trading News - Broker Roundup For Genocea Biosciences Inc (GNCA)Share Trading News03/03/2014 – Citigroup began new coverage on Genocea Biosciences Inc giving the company a “buy” rating. The share price of Genocea Biosciences Inc (GNCA) was down -1.25% during the last trading session, with a day high of 4.13. 456337 shares were ...Genocea Biosciences, Inc. (NASDAQ:GNCA) Closes At $3.9600Vanguard TribuneGenocea Biosciences Incorporated (NASDAQ:GNCA) Short Interest Decreased By 3.04%Wall Street Hints and Newsall 3 news articles »
05/23/16 05:07 PMGenocea Biosciences Inc (GNCA) Updated Price Targets - FTSE News - Genocea Biosciences Inc (GNCA) Updated Price TargetsFTSE News03/31/2016 – Genocea Biosciences Inc had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 17 price target on the stock. 12/17/2015 – UBS began new coverage on Genocea Biosciences Inc giving the company a ...Were Analysts Bearish Genocea Biosciences Inc (NASDAQ:GNCA) This Week?Franklin IndependentInvestors Are Watching: Genocea Biosciences, (NASDAQ:GNCA), ADDvantage Technologies Group (NASDAQ:AEY ...KC RegisterWhat's Next for Genocea Biosciences Inc After Today's Huge Increase?The PostThe Wall Street Transcriptall 5 news articles »
05/23/16 06:46 AMGenocea Appoints Dr. John E. Bishop as Senior Vice President of Pharmaceutical Sciences - [at noodls] - CAMBRIDGE, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that John ...
05/20/16 05:03 PMGenocea Biosciences Inc (GNCA) Jumps 11.39% on May 20 - Equities.com - Genocea Biosciences Inc (GNCA) Jumps 11.39% on May 20Equities.comGenocea Biosciences Inc (GNCA) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 11.39% to $4.01, representing a gain of $0.41 per share. Some 541,761 shares traded hands on 2,047 trades, compared with an ...Institutions are Taking Positions in Genocea Biosciences, Inc. (NASDAQ:GNCA)Franklin IndependentBroker Changes For Genocea Biosciences Inc (GNCA)Risers & FallersStock Seeing Gains in Session: Genocea Biosciences, Inc. (NASDAQ:GNCA)The PostKC Register -Benchmark Monitorall 13 news articles »
05/18/16 09:13 AMGenocea Biosciences Inc (GNCA) Jumps 9.97% on May 17 - Equities.com - Genocea Biosciences Inc (GNCA) Jumps 9.97% on May 17Equities.comGenocea Biosciences Inc (GNCA) was among the biggest gainers on the Russell 2000 for Tuesday May 17 as the stock popped 9.97% to $3.97, representing a gain of $0.36 per share. Some 1.16 million shares traded hands on 3,458 trades, compared with ...Genocea Biosciences Inc (NASDAQ:GNCA)'s Company Shares Decreased 37.76% After Low VolatilityWall Street Hints and NewsGenocea to Present at the 2016 UBS Global Healthcare ConferenceGlobeNewswire (press release)all 4 news articles »
05/17/16 04:57 PMGenocea Biosciences Inc (GNCA) Jumps 5.25% on May 16 - Equities.com - Genocea Biosciences Inc (GNCA) Jumps 5.25% on May 16Equities.comGenocea Biosciences Inc (GNCA) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 5.25% to $3.61, representing a gain of $0.18 per share. Some 247,239 shares traded hands on 1,253 trades, compared with an ...Stock Climbing Higher in Session: Genocea Biosciences, Inc. (NASDAQ:GNCA)The PostGenocea Biosciences Inc (NASDAQ:GNCA)'s Company Shares Decreased 37.76% After Low VolatilityWall Street Hints and NewsGenocea to Present at the 2016 UBS Global Healthcare ConferenceNasdaqall 5 news articles »
05/17/16 12:04 PMGENOCEA BIOSCIENCES, INC. Financials -
05/17/16 07:42 AMGenocea to Present at the 2016 UBS Global Healthcare Conference - [at noodls] - CAMBRIDGE, Mass., May 17, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management ...
05/15/16 05:31 PMGenocea Biosciences Inc (GNCA) Broker Price Targets For The Coming Week - Share Trading News - Genocea Biosciences Inc (GNCA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Genocea Biosciences Inc (GNCA). The latest reports which are currently in issue on Sunday 15th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
05/13/16 10:31 PMGenocea Biosciences Inc (GNCA) Drops 7.05% on May 12 - Equities.com - Genocea Biosciences Inc (GNCA) Drops 7.05% on May 12Equities.comGenocea Biosciences Inc (GNCA) was one of the Russell 2000's biggest losers for Thursday May 12 as the stock slid 7.05% to $3.43, a loss of $-0.26 per share. Starting at an opening price of $3.80 a share, the stock traded between $3.36 and $3.80 over ...Genocea Biosciences Inc (GNCA) Analyst ReviewRisers & Fallersall 2 news articles »
05/07/16 04:49 PMBiotech Movers: Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) , Genocea Biosciences, Inc. (NASDAQ:GNCA) - Is stories - Is storiesBiotech Movers: Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) , Genocea Biosciences, Inc. (NASDAQ:GNCA)Is storiesRock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) decreased -1.2330% to $0.0801 while traded 1.08 million shares on 5/6/2016. The stock price negotiated for value between $0.0801 to $0.0885 in recent trading session. During the past 52 weeks, the ...and more »
05/06/16 05:09 AMGENOCEA BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report -
05/05/16 05:40 PMAverage Analyst Rating for Genocea Biosciences, Inc. (NASDAQ:GNCA) - B.O.D.Y Confidential - Average Analyst Rating for Genocea Biosciences, Inc. (NASDAQ:GNCA)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.2 on Genocea Biosciences, Inc. (NASDAQ:GNCA) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/05/16 08:29 AMGenocea Biosciences reports 1Q loss -
05/05/16 07:42 AM8:42 am Genocea Biosciences reports Q1; GEN-003 Phase 2b virologic efficacy data expected in Q3 -
05/05/16 07:21 AMGenocea Reports First Quarter 2016 Financial Results - [at noodls] - 7d5765f8-03cd-430f-a050-befe1cdf437c.pdf May 5, 2016 - Positive 12-month efficacy data for GEN-003 for genital herpes strengthens value proposition - - Multiple 2016 clinical milestones for GEN-003 anticipated ...
05/05/16 07:14 AMGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/04/16 10:30 PMGenocea Biosciences Inc (GNCA) Drops 8.43% on May 03 - Equities.com - Web Breaking NewsGenocea Biosciences Inc (GNCA) Drops 8.43% on May 03Equities.comGenocea Biosciences Inc (GNCA) was one of the Russell 2000's biggest losers for Tuesday May 03 as the stock slid 8.43% to $3.91, a loss of $-0.36 per share. Starting at an opening price of $4.26 a share, the stock traded between $3.83 and $4.29 over ...Analysts Forecast Higher Genocea Biosciences Inc (GNCA) Earnings Per ShareFranklin IndependentGenocea Biosciences Inc (GNCA) Scheduled to Post Earnings on ThursdayWeb Breaking NewsGenocea Biosciences, Inc. (NASDAQ:GNCA) 50-day MA At $5.17Equities FocusStreet Updates -KC Registerall 6 news articles »
04/29/16 05:32 PMStocks under consideration: Genocea Biosciences(GNCA), Comfort Systems (FIX) - News Oracle - Stocks under consideration: Genocea Biosciences(GNCA), Comfort Systems (FIX)News OracleGenocea Biosciences Inc (NASDAQ:GNCA) declined -8.18% yesterday and closed at $4.60. The company's market capitalization is at $134.57 Million with an average trading volume of 2.37 Million. The total number of Outstanding Shares Held by the ...Stock Highlights: Editas Medicine Inc. (NASDAQ:EDIT), Genocea Biosciences, Inc. (NASDAQ:GNCA), Meritage Homes ...Benchmark MonitorGenocea to Host First Quarter 2016 Financial Results Conference Call & Webcast on May 5, 2016GlobeNewswire (press release)all 3 news articles »
04/29/16 05:32 PMGenocea Biosciences Inc (GNCA) Drops 8.18% on April 28 - Equities.com - Genocea Biosciences Inc (GNCA) Drops 8.18% on April 28Equities.comGenocea Biosciences Inc (GNCA) was one of the Russell 2000's biggest losers for Thursday April 28 as the stock slid 8.18% to $4.60, a loss of $-0.41 per share. Starting at an opening price of $5.05 a share, the stock traded between $4.56 and $5.05 over ...
04/28/16 07:19 AMGenocea to Host First Quarter 2016 Financial Results Conference Call & Webcast on May 5, 2016 - [at noodls] - CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it ...
04/28/16 03:53 AMGenocea Biosciences, Inc. (NASDAQ:GNCA) Share Rating Recap - B.O.D.Y Confidential - Genocea Biosciences, Inc. (NASDAQ:GNCA) Share Rating RecapB.O.D.Y ConfidentialShares of Genocea Biosciences, Inc. (NASDAQ:GNCA) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...and more »
04/27/16 10:46 PMGenocea Biosciences Inc (GNCA) Drops 6.92% on April 26 - Equities.com - Genocea Biosciences Inc (GNCA) Drops 6.92% on April 26Equities.comGenocea Biosciences Inc (GNCA) was one of the Russell 2000's biggest losers for Tuesday April 26 as the stock slid 6.92% to $4.84, a loss of $-0.36 per share. Starting at an opening price of $5.16 a share, the stock traded between $4.78 and $5.20 over ...
04/06/16 07:00 AMGenocea to Present at the 15th Annual Needham Healthcare Conference - [GlobeNewswire] - CAMBRIDGE, Mass., April 06, 2016-- Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company ...
04/05/16 08:21 AMGenocea Biosciences (GNCA) Shares March Higher, Can It Continue? -
About Genocea Biosciences

Genocea Biosciences logoGenocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company's pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GNCA
  • CUSIP:
Key Metrics:
  • Previous Close: $3.86
  • 50 Day Moving Average: $4.04
  • 200 Day Moving Average: $4.50
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $108.67M
  • Current Quarter EPS Consensus Estimate: $-1.74 EPS
Additional Links:
Genocea Biosciences (NASDAQ:GNCA) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha